ReviewFrontiers in medicine2022
Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 46 citations in OpenAlex.
- Arsenic exposure and skin cancer: Mechanisms, clinical evidence and public health implications (Review).International journal of molecular medicine · 2026Review
- Challenging interpretation of low-level PTCH1 mosaicism in patients with clinically diagnosed Gorlin syndrome: a case series and review of the literature.Hereditary cancer in clinical practice · 2026Article
- Identification of mitochondrial associated genes as diagnostic biomarkers for basal cell carcinoma: Comprehensive bioinformatics analysis and experimental validation.Glycoconjugate journal · 2026Article
- Refractory Morpheaform Basal Cell Carcinoma Successfully Treated with Oral Sonidegib.Clinical, cosmetic and investigational dermatology · 2026Article
- Immune signaling as a determinant of cellular identity and tissue function.Frontiers in immunology · 2026Review
- Autologous buccal mucosal graft combined with orbicularis oculi myocutaneous flap for single-stage reconstruction of full-thickness lower eyelid defects following Mohs micrographic surgery: a case report with literature review.Frontiers in oncology · 2026Article
- Mitophagy-driven immune evasion in skin cancer: multidimensional regulatory networks and context-dependent therapeutic strategies-a narrative review.Frontiers in immunology · 2026Review
- Case Report: High TMB fails to predict immunotherapy response inFrontiers in immunology · 2026Article
- Case Report: PTCH1 splice-site mutation and sonidegib treatment in Gorlin-Goltz syndrome: clinical insights from a family case study.Frontiers in medicine · 2026Article
- Multiple Basal Cell Carcinomas in a Long-Term Survivor of Childhood ALL and HSCT-A Call for Dermatologic Vigilance.Life (Basel, Switzerland) · 2025Review
- Cytotoxic Effects ofLife (Basel, Switzerland) · 2025Article
- Efficacy and safety of sonidegib in the treatment of locally advanced basal cell carcinoma: A multicenter retrospective experience in real-world China.Chinese medical journal · 2025Article
- A large unilateral basal cell carcinoma treated with Hedgehog inhibitor sonidegib: a case report.Dermatology reports · 2025Article
- Basal Cell Carcinoma: An Old Friend with Multiple Faces.Cancers · 2025Review
- Basal Cell Carcinoma Arising in a Previous Full-Thickness Graft Donor Site: A Case Report and Comprehensive Literature Review.Journal of clinical medicine · 2025Review
- Analysis of Body Composition and Levels of Antimicrobial Peptides in Patients with Basal Cell Carcinoma: A Preliminary Study.Journal of clinical medicine · 2025Article
- A Sonidegib Experience in the Treatment of Basal Cell Carcinoma with Systemic Lupus Erythematosus: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy.Frontiers in oncology · 2025Article
- Article
- Gorlin Syndrome-Associated Basal Cell Carcinomas Treated with Vismodegib or Sonidegib: A Retrospective Study.Cancers · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Basal cell carcinoma (BCC) is the most common form of skin cancer, affecting more often elderly patients, but sometimes even younger ones, particularly if immunocompromised or genetically predisposed. Specifically, the Gorlin-Goltz syndrome, an autosomal dominant genodermatosis, also known as nevoid basal cell carcinoma syndrome, characterizes for multiple early onset BCCs. It is caused by a germline mutation in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.